These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38807448)

  • 21. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.
    Socías ME; Wood E; Lake S; Nolan S; Fairbairn N; Hayashi K; Shulha HP; Liu S; Kerr T; Milloy MJ
    Addiction; 2018 Dec; 113(12):2250-2258. PubMed ID: 30238568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Willingness to pay for opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Marcus R; Bojko MJ; Madden L; Filippovich S; Dvoriak S; Altice FL
    Int J Drug Policy; 2017 Jul; 45():56-63. PubMed ID: 28628853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Barriers to retention in methadone maintenance therapy among people who inject drugs in Bangkok, Thailand: a mixed-methods study.
    Hayashi K; Ti L; Ayutthaya PPN; Suwannawong P; Kaplan K; Small W; Kerr T
    Harm Reduct J; 2017 Sep; 14(1):63. PubMed ID: 28882155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine.
    Galvez SJ; Altice FL; Meteliuk A; Ivasiy R; Machavariani E; Farnum SO; Fomenko T; Islam Z; Madden LM
    Front Public Health; 2023; 11():1231581. PubMed ID: 38098837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful transfer of stable patients on opioid agonist therapies from specialty addiction treatment to primary care settings in Ukraine: A pilot study.
    Meteliuk A; Galvez S; Fomenko T; Kalandiia H; Iaryi V; Farnum SO; Islam Z; Altice FL; Madden LM
    J Subst Abuse Treat; 2022 Mar; 134():108619. PubMed ID: 34579978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
    Saulle R; Vecchi S; Gowing L
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Marcus R; Pykalo I; Madden L; Filippovich S; Dvoriak S; Altice FL
    J Subst Abuse Treat; 2018 Apr; 87():1-8. PubMed ID: 29471921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine.
    Mazhnaya A; Marcus R; Bojko MJ; Zelenev A; Makarenko I; Pykalo I; Filippovych S; Dvoriak S; Altice FL
    J Acquir Immune Defic Syndr; 2018 Nov; 79(3):288-295. PubMed ID: 30312275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?
    Panagiotoglou D; Krebs E; Min JE; Olding M; Ahamad K; Ti L; Montaner JSG; Nosyk B
    Int J Drug Policy; 2017 Sep; 47():169-176. PubMed ID: 28578865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program.
    Bachireddy C; Shrestha R; Bromberg DJ; Azbel L; Kurmanalieva A; Wegman M; Shumskaya N; Rozanova J; Meyer JP; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103558. PubMed ID: 34915426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinics Optimizing MEthadone Take-homes for opioid use disorder (COMET): Protocol for a stepped-wedge randomized trial to facilitate clinic level changes.
    Choi S; O'Grady MA; Cleland CM; Knopf E; Hong S; D'Aunno T; Bao Y; Ramsey KS; Neighbors CJ
    PLoS One; 2023; 18(6):e0286859. PubMed ID: 37294821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
    Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
    Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
    [No Abstract]   [Full Text] [Related]  

  • 33. Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada.
    Guerra-Alejos BC; Yan Y; Kurz M; Mudalige N; Min JE; Homayra F; Nosyk B
    Addiction; 2024 Aug; 119(8):1453-1459. PubMed ID: 38584294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
    Brothers S; Viera A; Heimer R
    J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
    Paul LA; Bayoumi AM; Chen C; Kocovska E; Smith BT; Raboud JM; Gomes T; Kendall C; Rosella LC; Bitonti-Bengert L; Rush B; Yu M; Spithoff S; Crichlow F; Wright A; Watford J; Besharah J; Munro C; Taha S; Nosyk B; Strike C; Manson H; Kahan M; Leece P
    Addiction; 2023 Apr; 118(4):686-697. PubMed ID: 36401610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing.
    Corace K; Suschinsky K; Wyman J; Leece P; Cragg S; Konefal S; Pana P; Barrass S; Porath A; Hutton B
    Int J Drug Policy; 2022 Apr; 102():103573. PubMed ID: 35123246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using nominal group technique among clinical providers to identify barriers and prioritize solutions to scaling up opioid agonist therapies in Ukraine.
    Madden L; Bojko MJ; Farnum S; Mazhnaya A; Fomenko T; Marcus R; Barry D; Ivanchuk I; Kolomiets V; Filippovych S; Dvoryak S; Altice FL
    Int J Drug Policy; 2017 Nov; 49():48-53. PubMed ID: 28957756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of low-threshold methadone maintenance treatment on mortality in a Canadian setting.
    Nolan S; Hayashi K; Milloy MJ; Kerr T; Dong H; Lima VD; Lappalainen L; Montaner J; Wood E
    Drug Alcohol Depend; 2015 Nov; 156():57-61. PubMed ID: 26455554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of baseline methamphetamine/amphetamine use on discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder in Canada.
    Langlois J; Fairbairn N; Jutras-Aswad D; Le Foll B; Lim R; Socías ME
    Am J Addict; 2024 Nov; 33(6):664-674. PubMed ID: 38877969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opioid agonist treatment and the process of injection drug use initiation.
    Mittal ML; Jain S; Sun S; DeBeck K; Milloy MJ; Hayashi K; Hadland SE; Werb D
    Drug Alcohol Depend; 2019 Apr; 197():354-360. PubMed ID: 30922483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.